Can Merck Keep Its Bull Run Going?

Shares in Merck have made a strong start to 2014. Can they keep going?

Mar 10, 2014 at 2:30PM

Shareholders in Merck (NYSE:MRK) have enjoyed the first couple of months of 2014, since shares in the company are up 15%. This easily beats the S&P's return of 1.5% over the same time period. However, can Merck keep the bull run going?

Potential catalysts
Merck released details this week of a phase 2 trial involving a combination of Merck's MK-5172 and MK-8742 to treat patients co-infected with HIV and hepatitis C. The administration of the combination for 12 weeks resulted in robust hepatitis C suppression, which is positive news for Merck. Further news flow concerning the combination could act as a catalyst on the share price, with further details set to be released in April. 

In addition, Merck received positive news flow regarding a mid-stage study for an oral treatment for house dust mite reactions. In a phase 2b trial, Merck's MK-8237 improved 24-week nasal symptoms by 49% at its highest dosage, with the drug also delivering promising dose and time-dependent reductions compared to placebo at eight and 16 weeks. Merck will now push ahead with a phase 3 trial in the relatively near future.

Of course, the largest reason for Merck's shares performing strongly in 2014 are developments surrounding its PD-1 drug, MK-3475. Merck announced plans to partner with three major biopharma companies (Amgen, Pfizer, and Incyte) in January, with the group all set to combine MK-3475 with other drugs in clinical trials. Furthermore, Merck will also increase its own work on the drug, with the company announcing early-stage studies for 20 different PD-L1-positive solid tumor types that have not yet been explored. The results of the trials (and other developments surrounding MK-3475) could have a major impact on Merck's share price.

A potential challenge
Although developments surrounding MK-3475 have been encouraging, sector peer Bristol-Myers Squibb (NYSE:BMY) has just this week announced that it will commence a phase 3 trial by the end of the year for its rival to MK-3475, nivolumab. The market had been surprised at how slowly Bristol-Myers Squibb had moved to a phase 3 trial after the drug impressed in its phase 2 trial. Developments surrounding both drugs are likely to act as catalysts on the share prices of both Merck and Bristol-Myers Squibb going forward.

While Merck has a number of potential catalysts, sector peer AbbVie (NYSE:ABBV) has also released positive news flow of late. For instance, AbbVie's hepatitis C combination treatment cured almost 100% of patients in a phase 3 trial recently. It is one of six late-stage studies that AbbVie completed to form part of an FDA application, with the company still aiming to make the submission by the end of the first half of 2014. The outcome could have a significant impact on AbbVie's share price as sales projections for the drug were not included in its most recent set of results.

Merck's 2014
So, recent news flow has been strong for Merck and has been a key reason why shares have made such a strong start to the year. Indeed, there are a number of potential catalysts (notably the potential progress of Merck's MK-3475 and Bristol-Myers Squibb's nivolumab) that could have a significant impact on the future share price of both companies. As a result, 2014 could continue to be a strong year for Merck, and it looks all set to keep its bull run going.

Another stock that could have a bull run this year
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Peter Stephens has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information